Serial analysis of gene expression followed by pathway analysis implicated the tight junction protein claudin-1 (CLDN1) in melanoma progression. Tight junction proteins regulate the paracellular transport of molecules, but staining of a tissue microarray revealed that claudin-1 was overexpressed in melanoma, and aberrantly expressed in the cytoplasm of malignant cells, suggesting a role other than transport. Indeed, melanoma cells in culture demonstrate no tight junction function. It has been shown that protein kinase C (PKC) can affect expression of claudin-1 in rat choroid plexus cells, and we observed a correlation between levels of activated PKC and claudin expression in our melanoma cells. To determine if PKC could affect the expression of CLDN1 in human melanoma, cells lacking endogenous claudin-1 were treated with 200 nM phorbol myristic acid (PMA). PKC activation by PMA caused an increase in CLDN1 transcription in 30 min, and an increase in claudin-1 protein by 12 h. Inhibition of PKC signaling in cells with high claudin-1 expression resulted in decreased claudin-1 expression. CLDN1 appears to contribute to melanoma cell invasion, as transient transfection of melanoma cells with CLDN1 increased metalloproteinase 2 (MMP-2) secretion and activation, and subsequently, motility of melanoma cells as demonstrated by wound-healing assays. Conversely, knockdown of CLDN1 by siRNA resulted in the inhibition of motility, as well as decreases in MMP-2 secretion and activation. These data implicate claudin-1 in melanoma progression.
Introduction
Melanoma is among the deadliest of all skin cancers, and its incidence continues to increase rapidly. To better understand the molecular mechanisms of this disease, we previously initiated a serial analysis of gene expression (SAGE) study (Weeraratna et al., 2004) . Data from this study are publicly available at http://cgap.nci.nih. gov/SAGE/SALL?ORG ¼ Hs (skin libraries, SAGE_s kin_melanoma_ DB1 and DB2). Pathway analysis of these data revealed claudin-1 (CLDN1), as differentially expressed in metastatic melanoma. Other claudins, such as the gene encoding claudin-3 (CLDN3), were either not upregulated in the melanoma SAGE libraries, or were upregulated not only in melanoma (CLDN4), but also in other cancers.
Claudins are important in tight junction (TJ) formation and control paracellular transport. TJs are critical structures for the maintenance of cellular polarity, involved in paracellular transport and in cellular growth and differentiation (Gonzalez-Mariscal et al., 2003) . Claudin proteins are known to directly interact with the zona occludens (ZO) proteins ZO-1, ZO-2 and ZO-3, and provide a critical structural component of the TJ (Heiskala et al., 2001) . Claudin-1 and -4 have been shown to be important in the maintenance of barrier integrity in the epidermis, as claudin-1-deficient mice die within 1 day of birth, owing to defects in the epidermal barrier (Furuse et al., 2002) .
Tumors exhibit a loss of organization associated with a decrease in TJ integrity (Swisshelm et al., 2005) , potentially allowing diffusion of nutrients and other growth factors, and facilitating the escape of the tumor cells into the vasculature (Sawada et al., 2003) . Thus, the regulation of TJs is of significant interest in cancer biology, and claudins in particular, have been the focus of some attention, as these proteins are frequently upregulated and mislocalized in cancer, suggesting abnormal processing (reviewed in Morin, 2005) . Data exist that connect protein kinases to this pathway (D'Souza et al., 2005) . Claudin-1 is currently the only known claudin protein that can undergo an increase in expression, and a translocation from the membrane to the cytoplasm upon activation of protein kinase C (PKC) in rat choroid plexus epithelial cells (Lippoldt et al., 2000) . PKC activation is a hallmark of melanoma metastasis and motility, and its inhibition can result in the inhibition of metastases in vitro and in vivo (Dumont et al., 1992; Nakamura et al., 2003) . Thus, we initiated an investigation of claudin-1 expression in melanoma, and its relationship to PKC signaling and motility in a tumorigenic setting.
Results

Claudin-1 is highly and aberrantly expressed in melanoma
The melanoma tissue microarray, which has been previously described by Pollock et al. (2003) , contains samples ranging in stage from nevi to visceral metastases. In the epidermis, claudin-1 was highly expressed at the cell-cell junctions, as expected ( Figure 1 , (E), Nevi and magnification). In nevi, claudin-1 was completely absent in about 57% (17/30 samples). Where present, all staining was nuclear ( Figure 1, (N) , nevi) except for two samples that also had cytoplasmic staining. In primary melanomas, more samples expressed claudin-1 (24 out of 28, or 86%). Claudin-1was also present in the cytoplasm as well as the nucleus (12/24 positive samples), and sometimes at the junctions as well (4/24 positive samples), but was never present exclusively at the junctions (Figure 1, primary) . Claudin-1 staining was present exclusively in the nucleus in only one sample, and exclusively in the cytoplasm in 7/24 samples. Overall, nuclear staining could be found in about 60% of the positive samples, of which all but one also had cytoplasmic staining. This was true also of dermal metastases (Figure 1, dermal) , where the same proportion of cells showed nuclear claudin-1 staining (20/33 positive samples), but more samples (7/33) were exclusively nuclear in their staining pattern. Four samples also showed junctional, as well as cytoplasmic staining. Overall, 33/42, or 79% of all dermal metastases stained positive for claudin-1. In subcutaneous metastases (Figure 1, SubQ) , the proportion of samples with nuclear claudin expression dropped significantly. Overall, 37/45 (82%) of all samples were positive for claudin-1. Of these, only 27% (10/37) had both nuclear and cytoplasmic staining (none had nuclear only) and five samples had junctional, as well as cytoplasmic staining. Eighty-one percent (21/26) of lymph node metastases (Figure 1 , (L), lymph) were positive for claudin-1. In this metastatic subtype, however, the expression of claudin-1 was overwhelmingly cytoplasmic, with only one sample staining nuclear as well as cytoplasmic (no samples were exclusively nuclear) and two samples staining junctional, as well as cytoplasmic. This was the only subtype that had so few samples that did not stain for nuclear claudin-1. Visceral metastases (Figure 1 , visceral) stained positive at a rate of 89% (39/44). Like subcutaneous metastases, this positivity was also largely cytoplasmic, with about 31% of the positive samples having nuclear staining (12/39) and about 18% (7/39) with junctional, in addition to cytoplasmic staining. Statistical evaluation of the results showed that the lack of cytoplasmic staining in the nevi as compared to the primary samples was significant to a P-value of 0.00002. This was even more significant when compared with the metastatic samples (P-values ranged from 4.48 Â 10 À7 to 1.55 Â 10 À11 ). There was no significant difference between the primary cancers and dermal metastases, but P-values ranged between 0.07 and 0.0005 between primary cancers and other metastases. The staining results are summarized in Table 1 .
To further investigate the role of claudin-1 in melanoma, we ascertained its presence in several Figure 1 Claudin-1 staining of a melanoma tissue array. In nevi, there is staining in only half of all samples, and it is predominantly nuclear (N), whereas the epidermis (E) shows strong staining only at the cell junctions (E, and blow ups). Primary melanoma has strong staining in the cytoplasm and nucleus of the cells, as do dermal metastases (M). Subcutaneous (SubQ), lymph node (L) and visceral metastases have decreased nuclear staining, but high amounts of cytoplasmic staining for this protein. All staining shown here are 2 þ and stronger. See the Results section and Table 1 for details.
Claudin-1 expression in melanoma PD Leotlela et al cultured cell lines. The majority of cell lines had high levels of CLDN1 expression by real-time polymerase chain reaction (PCR) (Figure 2a ) and Western analysis (Figure 2b ). OVCA433 ovarian cancer cells were used as a positive control for claudin-1 expression. Normal melanocytes (HEMN) exhibited low levels of claudin-1, perhaps owing to the necessity for these cells to exist in an organized structure within keratinocytes in the epidermis. Claudin-3 was not widely expressed in melanoma, and in fact appeared to be downregulated, perhaps contributing to the low levels of transepithelial resistance (TER) seen in these cells (Supplementary Claudin-1 expression in melanoma PD Leotlela et al Figure 2a ). Claudin-4, although widely expressed in melanoma, was not as highly expressed as claudin-1 (Supplementary Figure 2b) . This observation is interesting in the context of epidermal barrier integrity, as it has been shown that claudin-1 and -4 act together to form functional TJs in mammalian skin (Furuse et al., 2002) . However, the high expression of claudin-1 did not appear to correlate to its normal function, as none of the melanoma cell lines had any functional TJs, as measured by a TER assay (Figure 2c ). Immunofluorescent staining of melanoma cells showed that claudin-1 expression, as in the patient biopsies, was no longer at the cell-cell junctions but instead was now expressed in the cytoplasm as well (Figure 2d ). Differences in the confluency of the cells did not alter either expression or localization of claudin-1. Madin-Darby canine kidney (MDCK) cells have highly functional TJs and were used as a positive control for both TER and immunofluorescent staining. MDCK cells showed claudin-1 expression largely at the cell junctions ( Figure 2d ), which correlated to functional TJs ( Figure 2c ).
Claudin-1 expression is regulated by PKC in melanoma
As PKC activation is a key element of melanoma progression (Dumont et al., 1992; Nakamura et al., 2003) , and as we observed that levels of claudin-1 correlated to levels of active, phospho-PKC in our cell lines, we examined whether indeed PKC could directly affect the expression of claudin-1 in melanoma cells. To this end, we selected two melanoma cell lines with endogenously low claudin-1 expression ( Figure 3a , 1205LU and G361), and correspondingly low levels of phospho-PKC and two melanoma cell lines with high claudin-1 ( Figure 3a , UACC903 and UACC647), and high phospho-PKC. Interestingly, the subcellular localization of claudin-1 reflected the tissue staining-less motile cells had either almost no staining (G361), or staining was nuclear (1205LU), and more motile cells (UACC647, UACC903) had high levels of cytoplasmic claudin-1. Cells with low claudin-1 expression (1205LU, G361) were treated with 200 nM phorbol myristic acid (PMA) for a series of time points and claudin-1 expression was examined by real-time polymerase chain reaction ( Figure 3b ) and Western blot analysis ( Figure 3c ). In all cases, activation of PKC by PMA resulted in concomitant increases in claudin-1 expression. Interestingly, immunofluorescence reveals that staining of claudin-1 in 1205LU cells is low, and confined to the nucleus (Figure 3d , 1205LU). Treatment of these cells with PMA results not only in an increase in expression of claudin-1, but also a shift out of the nucleus ( Figure 3d , 1205LU-PMA-12h). Claudin-3 and -4 did not exhibit such a significant, sustained increase in expression upon PMA treatment (Supplementary Figure 2c) . Interestingly, immunofluorescence reveals that staining of claudin-1 in 1205LU cells treated with a vehicle control is low, and confined to the nucleus, as in the untreated cells ( Figure 3a and d, 1205LU-veh).
Treatment of these cells with PMA for 12 h results in a shift out of the nucleus (Figure 3d , 1205LU-PMA-12h).
In addition, cells with high claudin-1 (UACC647, UACC903) were treated with specific inhibitors of conventional PKCs. UACC647 were treated with Go6 983 (a specific inhibitor of PKC a, b, g, d and z, but not m) and UACC903 cells were treated with GF 109203X (inhibitor of PKC a, b, d and e) in an attempt to use two different inhibitors of the conventional PKC pathway. Real-time reverse-transcriptase (RT)-PCR ( Figure 3e ) and Western blot analysis (Figure 3f) showed that the inhibition of PKC resulted in a concomitant inhibition of claudin-1 expression by both inhibitors, implicating the a, b and d isoforms in this inhibition. Immunofluorescence did not show a shift in subcellular locale of this protein, but merely a decrease in its expression upon treatment with the PKC inhibitors (data not shown), reflecting the Western blot data. Interestingly, PKC inhibitors showed no effect on claudin-3 and -4 expression in UACC647 cells (Supplementary Figure  2d ), but had a dramatic effect on claudin-3 and -4 in UACC903 cells, where contrary to claudin-1 expression, the expression of claudin-3 and -4 was dramatically increased upon inhibition of PKC (Supplementary Figure 2d) . It is not yet clear how the inhibition of PKC in these particular cells can result in the increase of claudin-3 and -4, while decreasing claudin-1, but does strongly suggest that claudin-3 and -4 do not require PKC activity for their expression in melanoma cells.
Claudin-1 expression leads to increases in matrix metalloproteinases Miyamori et al. (2001) have linked claudin-1 to increases in matrix metalloproteinase 2 (MMP-2) and MMP-2 is crucial for the CXCL12-mediated migration of melanoma cells (Bartolome et al., 2006) . To confirm the correlation between the expression of MMP-2 and motility of melanoma cells in our system, levels of MMP-2 were examined among a panel of cell lines, and compared to their motility in a wound-healing assay. The levels of MMP-2 correlated to the time taken to heal a wound in a wound-healing assay (Figure 4a ). Further evidence of an important role for MMP-2 in our melanoma cells could be seen by treating high MMP-2-expressing cells (UACC903 and UACC647) with an MMP-2/9 inhibitor, which resulted in a dramatic decrease in MMP-2 activation and secretion (Figure 4b) , and also in a dramatic inhibition of the ability of these cells to heal a wound ( Figure 4c ). As the UACC647 cells do not express detectable MMP-9, we can assume that, at least in these cells, a large part of their ability to close a wound is dependent on MMP-2. Levels of claudin-1 correlated to MMP-2 secretion, as, in cells with high claudin-1 expression (Figure 2b) , there was increased expression of MMP-2, and vice versa (Figure 4a ). To ascertain if claudin-1 could directly activate MMPs in melanoma cells, low claudin-1-expressing cells were transfected with claudin-1 (Figure 5a ). Claudin-1 overexpression caused an activation of MMP-2 (Figure 5b) , as evidenced by the appearance of the 66-kDa active form of MMP-2 (Figure 5b, arrow) . In addition, claudin-1 and Claudin-1 expression in melanoma PD Leotlela et al mock-transfected G361 cells were stained immunofluorescently for claudin-1 and MMP-2. Confocal microscopy demonstrates significant increases in the amount of cellassociated MMP-2 in claudin-1-transfected G361 cells (Figure 5c and d) . Cells that endogenously expressed high levels of claudin-1 were transfected with siRNA against claudin-1 (Figure 5e ). Gelatin zymography revealed a downregulation of MMP-2 secretion and activation 48 h after transfection (Figure 5f ). These data suggest that MMP-2 is important for melanoma cell motility, and that its expression can be affected by claudin-1.
Claudin-1 expression contributes to melanoma cell motility To ascertain whether increasing or decreasing claudin-1 itself would directly affect invasion, cells were transfected with claudin-1, and assayed for their invasive Claudin-1 expression in melanoma PD Leotlela et al capability using a wound-healing assay. Our data demonstrate that cells transfected with claudin-1 show an increase in motility ( Figure 6a ) and are able to close a scratch wound much faster than the mock-transfected controls. Indeed, after 72 h, the mock-transfected cells at the edge of the scratch start to die and the scratch begins to widen (Figure 6a, arrows) . Conversely, in cells, which are highly motile and have high claudin-1 expression, siRNA inhibition of claudin-1 results in an inhibition of their motility, causing them to take up to twice as long to close the scratch (Figure 6b ). Taken together, these data indicate that claudin-1 expression can be regulated by PKC in melanoma cells, and that claudin-1 overexpression contributes to melanoma cell motility.
Discussion
Claudin-1 is aberrantly expressed in melanocytic lesions.
Whereas it is present at the cell-cell junctions of cells that comprise the epidermal layer, only about half of nevi express claudin-1, exclusively in the nucleus. This nuclear staining is also present both in primary melanoma and dermal metastases, but in addition to many more claudin-1-positive primary melanomas, many exhibit cytoplasmic claudin-1. In both subcutaneous and visceral metastases, the nuclear claudin-1 is drastically reduced, though cytoplasmic claudin-1 remains highly expressed, and in lymph node metastases, there is almost no nuclear claudin-1. Why this loss of nuclear claudin-1 occurs in the more metastatic stages of melanoma is unclear, but may indicate an association between claudin-1 sublocalization and metastatic potential. The absence of nuclear staining in the epidermis, and in metastases leads us to believe that this nuclear staining is not an artifact, and indeed not only claudin-1 (Dhawan et al., 2005) , but other TJ proteins show a similar propensity. ZO-2, for example, can inhibit AP-1 and C/EBP transcription factors upon its entry into the nuclei of proliferating cells (Betanzos et al., 2004) . On the other hand, the expression of nuclear claudin-1 in these cells may simply be an effect of the surrounding microenvironment as nevi, primary melanoma and dermal metastases are all found in the same general microenvironment in the epidermis. However, our in vitro data also demonstrate that highly metastatic cells have cytoplasmic claudin-1, and those with low metastatic potential have either no claudin-1 or nuclear claudin-1. PKC activation in the latter results in the Figure 4 MMP-2 is important in melanoma cell migration. (a) Gelatin zymography was used to assess MMP-2 secretion in melanoma cell lines that took over 48 h to heal a scratch wound (G361 and 1205LU) in a wound-healing assay and melanoma cell lines that took less than 24 h to heal a similar size scratch wound (M93-047, UACC647 and UACC903) (upper panel). Cell lines with low MMP-2 activation (G361 and 1205LU) were slow to close a scratch wound, and those with high levels of MMP-2 secretion and activation are quick to do so (M93-047, UACC647 and UACC903). Time taken to close the scratch wounds is indicated below the zymogram.
(b) Inhibition of MMP-2, by 3 mM MMP-2/9 inhibitor, in UACC647 and UACC903 cells resulted in an almost complete inhibition of MMP-2 secretion and activation. MMP-9 is almost undetectable by zymography in these cells (not shown). Arrow indicates the cleaved, active form of MMP-2 at 66 kDa. R is recombinant MMP-2, U is untreated and 24 h and 48 h represent treatment times. (c) MMP-2 activation was inhibited by incubating UACC647 cells on collagen IV matrix with 3 mM MMP-2/9 inhibitor for 24 and 48 h. Inhibition of MMP-2 activation corresponded to the inability of cells to close a scratch wound, such that cells that were inhibited for longer (48 h) took more than 24 h to close the wound.
Claudin-1 expression in melanoma PD Leotlela et al translocation of claudin-1 to the cytoplasm. The exact role of nuclear claudin-1 in melanoma cell proliferation and metastasis is an area of future study for our laboratory. In addition, the acquisition of paired samples (primary lesions paired with metastatic samples) is currently underway to determine if we can associate both time to metastasis, as well as patient outcome (survival) to the levels and importantly, the subcellular locale of claudin-1. It is unclear why the expression of TJ proteins should be upregulated in cancer, especially in cell types that normally do not form TJs. Our data, and others, indicate that these proteins are playing a role completely unrelated to their TJ function, and may instead be contributing to changes that result in increases in tumor progression (reviewed in Morin, 2005) . In melanoma specifically, an elegant study by Smalley et al. (2005) demonstrates that other TJ proteins such as ZO-1 also have increased expression, and inhibition of ZO-1 expression by siRNA results in a loss of metastatic potential in melanoma cells. Our data do however, directly contradict a recent study that found a loss of claudin-1 expression by immunohistochemistry in metastatic melanoma as compared with benign and primary lesions (Cohn et al., 2005) . Because the claudin-1 antibody is polyclonal, it is possible that differences in antigen unmasking may result in differences in staining, or that their samples reflect a specific subset of melanoma. The nevus and primary samples on our tissue microarray are a collection of samples from various institutes, and the metastatic samples are largely derived from a population of patients who have failed numerous previous therapies. Furthermore, as demonstrated here, our data were supported both by real-time RT-PCR and Western analysis of melanoma cells and melanocytes, as well as by our SAGE library data.
Instead, our data more closely mirror two recent studies of claudin-1 expression in cancer. The first is an extensive study of claudin-1 expression in colon cancer (Dhawan et al., 2005) , which found that claudin-1 was aberrantly expressed both in the cytoplasm and in the nucleus, as demonstrated not only by Claudin-1 expression in melanoma PD Leotlela et al immunohistochemistry and immunofluorescence, but also by Western analysis of nuclear and cytoplasmic fractions. The second study was conducted in oral squamous carcinoma (OSC) cells, and found that claudin-1 overexpression enhanced the invasion of OSC cells via increases in MMP-2. As with our current study in melanoma, treatment of OSC cells with claudin-1 siRNA could inhibit the activation of MMP-2, and decrease invasion (Oku et al., 2006) . Both these studies, and others, have demonstrated that the presence of cytoplasmic TJ proteins is associated with the tumorigenicity of cancer cells (Rangel et al., 2003; Morin, 2005) , and our data suggest that this may also be true for melanoma, and claudins may be involved not just at TJs, but as targets of signal transduction. It has been shown previously that PMA can increase the levels of claudin-1, as well as cause relocation in its subcellular localization in rat choroid plexus cells (Lippoldt et al., 2000) , but does not affect the expression or localization of other claudins such as claudin-2 and -5. We found this to be true for human melanoma cells as well, as using phorbol ester increased the expression of claudin-1 in cells that had little claudin-1, and the converse was also true, that is, in cells with high claudin-1 using a specific inhibitor of the conventional PKC pathway reduced claudin-1 expression. However, we saw very little effect of PMA activation on either claudin-3 or -4 (Supplementary Figure 2c) , both of which are commonly upregulated in other human cancers. Our PKC data lent credence to the hypothesis that claudin-1 might be involved in melanoma malignancy, as PKC is known to be important for melanoma metastasis, and our laboratory as well as others, have shown that mechanisms which upregulate PKC can result in increases in melanoma cell motility (Weeraratna et al., 2002) . In addition, PKC activation can increase levels of MMPs, via the p38MAPK pathway (da Rocha et al., 2000; Park et al., 2003) . Further data from our laboratory support this observation, showing that the activation of conventional PKCs using phorbol ester results not only in the increase of claudin-1, but also in the increase of MMP-2 secretion (data not shown). Given the fact that MMP-2 does not have a TPAbinding site as do most other MMPs, it is likely that PKC activation is leading to increases in MMP-2 via changes in other proteins, such as claudin-1, especially as increases in MMP-2 secretion do not occur for several hours after PMA treatment. Interestingly, in our melanoma lines, the level of MMP-2 was significantly higher than the levels of MMP-9, which was undetectable by zymogram in some highly metastatic cells (e.g., UACC647). In addition, in UACC903 cells, which have low levels of MMP-9, inhibition of claudin-1 expression had no effect on MMP-9 secretion/activation (data not shown), suggesting that whereas MMP-2 might be under the direct regulation of claudin-1 in melanoma cells, Claudin-1 expression in melanoma PD Leotlela et al MMP-9 is not. In support of these data, a recent paper shows that MMP-2, but not MMP-9, contributes to melanoma cell invasion (Bartolome et al., 2006) , and in OSC, claudin-1 manipulation can also affect MMP-2 and MT-MMP1 (Oku et al., 2006) . In other cancer types, where MMP-9 is the more predominant MMP, it may be that claudin-1 has more specific effects on that enzyme. In addition, we also show that inhibiting MMP-2 in cells that have no MMP-9 (UACC647) dramatically reduces their motility in a wound-healing assay, again pointing to the importance of MMP-2 and its regulation by a claudin-dependent pathway in melanoma.
We demonstrate here for the first time, that claudin-1 is aberrantly expressed in melanoma and is able to increase melanoma cell migration, and that the targeted inhibition of claudin-1 can result in a decrease in this migration. This observation is in keeping with the fact that other TJ proteins such as ZO-1 have the same effects on melanoma metastasis (Smalley et al., 2005) . The increase of claudin-1 is regulated by PKC, and provides further evidence that the activation of PKC can have multiple effects on melanoma migration, from the activation of signal transduction cascades to dysregulation of TJ proteins. Direct phosphorylation of claudin-1 by PKC may result in the disruption of TJ function in cancer cells, providing yet another reason for the importance of PKC inhibitors in cancer therapy. Although targeting claudin-1 itself may prove to be difficult, considering the high levels of this protein in normal skin, the fact that it may be directly phosphorylated by PKC could provide a modified form of claudin-1 that could be of use as a molecular target. Finally, claudin-1 may prove to be a valuable marker for melanoma progression, especially if it is found that the loss of nuclear claudin-1, concomitant with an increase in cytoplasmic claudin-1, correlates to clinical outcome.
Materials and methods
Tissue array analysis
Immunohistochemistry was performed on a melanoma tissue microarray constructed as previously described (Pollock et al., 2003) . Antigen retrieval was also performed as described in this reference. For details of antibodies, staining and statistics please see Supplementary materials.
Real-time PCR analysis
Primers were designed for use with the ABI 7700 system (Applied Biosystems Inc., Warrington, UK). Primers were designed to generate products of less than 200 bp, for efficient analysis. For details and primer sequences, see Supplementary materials.
Cell lines
The human melanoma cell lines UACC903, 1205LU and UACC647 were cultured in Rosewell Park Memorial Institute (RPMI)-1640 media (Gibco-BRL, Bethesda, MD, USA) supplemented with 10% fetal bovine serum (FBS) (Hyclone, Logan, UT, USA), 100 U/ml penicillin G and 100 U streptomycin (Gibco-BRL, Bethesda, MD, USA). 1205LU cells were a generous gift from Dr Meenhard Herlyn (Wistar Institute, Philadelphia, PA, USA). G361 cells were maintained in McCoy's 5A medium (Gibco-BRL, Bethesda, MD, USA) with 5% FBS. HEMN cells (Cascade Biologics, Portland, OR, USA) were maintained in medium 254, with human melanocyte growth supplement (Cascade Biologics, Portland, OR, USA). All cell cultures were incubated at 37 o C in 5% CO 2 / 95% air, and the medium was replaced every second day.
TER measurements
Cells were plated at a density of 50 000 cells/well in 12-well Transwell filters. The TJ epithelial resistance (TER) was measured over 4 days using a Millicell-ERS epithelial V-ohmmeter (World Precision Instruments, New Haven, CT, USA). The TER values were calculated by subtracting the blank values from the sample values and normalized to the growth area of the monolayer.
Immunofluorescence
For claudin-1 staining, cells were grown on glass slides, and allowed to reach 80% confluency, then fixed and stained as previously described (Weeraratna et al., 2002) . Claudin-1 antibody (rabbit anti-claudin-1, Zymed Laboratories, San Francisco, CA, USA) was used at a concentration of 1 : 50, and MMP-2 antibody (goat anti-human MMP-2, R&D Systems, Minneapolis, MN, USA) at 10 mg/ml. The secondary antibodies used were anti-goat 594, and anti-rabbit 488 (Alexa fluor antibodies, Invitrogen, Carlsbad, CA, USA). Cells were imaged using a Zeiss LSM 510 Meta confocal microscope (Thornwood, NY, USA).
CLDN1 expression vector and siRNA CLDN1-specific siRNA oligonucleotides were obtained from Dharmacon RNA Technologies (Chicago, IL, USA) using their Smartpool technique. This technique combines at least four siRNA sequences against the gene to assure efficient knock down of the gene product. Full-length cDNA for CLDN1 was amplified from human ovarian cancer cell-line OVCA433 following RNA extraction and reverse transcription. Reverse transcription was performed on 1 mg RNA with the iScript cDNA synthesis kit (Bio-Rad Laboratories, Hercules, CA, USA), according to the manufacturer's instructions. For amplification of CLDN1, the primers used were CCCCGCCTTAACTTCCTC and CTCCTTTTGCCTCTGT GTCA. The resulting 772 bp fragment was cloned into mammalian expression vector pcDNA3.1/V5-His using the TOPO TA expression kit, according to the manufacturer's instructions (Invitrogen, Carlsbad, CA, USA). The correct sequence and orientation of all constructs was verified by direct DNA sequencing.
Transfections
Cells were allowed to reach 60-70% confluency within 48 h of seeding. The cells were transfected with either CLDN1 siRNA, CLDN1 expression vector or the empty vector controls, using lipofectamine (Gibco-BRL, Bethesda, MD, USA). After 6 h of transfection, the medium was replaced with fresh serumcontaining medium. Transfection efficiencies are usually around 75% for plasmid transfection, as gauged by simultaneous green fluorescent protein (GFP) transfection, and above 90% for siRNA oligos, as gauged by transfection with rhodamine-tagged siRNAs. Interestingly, transfection efficiency is highly dependent on melanoma cell confluency, and cell densities higher than 80% result in inefficient transfection. This data is available from the authors upon request.
Western blotting
Phospho-Pan-PKC antibody was obtained from Cell Signaling Technologies (Beverly, MA, USA). Claudin-1 antibody was obtained from Zymed Laboratories (San Francisco, CA, USA). Western analysis was performed as previously described (Weeraratna et al., 2002) .
Gelatin zymography
The cell-conditioned medium was concentrated using Centriplus YM-10 columns (Millipore, Billerica, MA, USA) and the protein concentration was determined using the BCA protein assay kit (Pierce, Rockford, IL, USA). Thirty micrograms of protein was separated in non-reducing conditions in a 10% zymogram gel containing 0.1% gelatin (Invitrogen, Carlsbad, CA, USA). After electrophoresis, gels were incubated in zymogram renaturing buffer at room temperature for 30 min to remove the SDS, followed by a 24-h incubation at 371C in the zymogram developing buffer (Invitrogen, Carlsbad, CA, USA). Gels were then stained for 2 h in 30% methanol, 10% glacial acetic acid and 0.25% Coomassie blue and destained for 4 h in 10% methanol/10% glacial acetic acid. Clear bands appear on the Coomassie blue-stained background in the areas of gelatinolytic activity. Experiments were repeated with at least four independent sets of culture medium.
Wound-healing assays
Wound-healing assays were performed by plating cells in slide chambers coated with fibronectin, collagen I or collagen IV (each cell line was assayed on all matrices). After cells were allowed to attach and reach confluency, a scratch, or wound, was made through the fibronectin or collagen I or collagen IV, using a sterile pipette tip. Photographs of cells invading the scratch were taken at the indicated time points. Assays were performed in triplicate for each condition.
MMP-2 and PKC inhibition assays MMP-2/MMP-9 activity was inhibited by incubating cells with MMP-2/MMP-9 inhibitor II (Calbiochem, San Diego, CA, USA). Cells were grown to 80-90% confluency on plates coated with type IV collagen, and then treated with 3 mM of MMP-2/MMP-9 inhibitor II for 24 h and/or 48 h in serum-free medium. Media was collected and concentrated as described above, for gelatin zymography and wound-healing assays. For PKC inhibition studies, a range of times, concentrations and inhibitors was tested, and ultimately, Go¨6983 and GF 109203X (Calbiochem, San Diego, CA, USA) were used at concentration of 1 mM each.
